 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...6061626364656667686970...143144» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Blood tests to predict one- to two-year survival of patients with difficult cancers. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4315;
P2
Ts warrant development: validation with GFLIO and other therapy and other cancers; to improve Ts, models for eligibility and geriatric criteria; to identify false -/+ trials; and personalize trials to correct UnF Ts . FTs, with GFLIO, can change prognosis and practice for > 50% of pts now advised “against” any therapy due to a clinical estimate of “less than 6 -10 mos to live.”
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Rationale for the utilization of biological targeted agents (bTAs) in the treatment of metastatic colorectal cancer (mCRC), single tertiary cancer center experience. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4153;
We were not able to detect any significant difference among the three groups of comparison . The 1LaEGFR available data in this subset of patients are limited .
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy and prognostic significance of triflurodine/tipiracil beyond oxaliplatin and irinotecan based chemotherapy in patients with refractory metastatic colorectal cancer: An observational multicenter study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4150;
Trifluridine/tipiracil is effective in patients with refractory mCRC . The low neutrophil count might predict a better overall survival.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A retrospective analysis of real-world time on treatment and overall survival in patients with metastatic colorectal cancer receiving cetuximab in third line. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4139;
The most common treatment regimens in 1L and 2L were FOLFOX and FOLFIRI respectively . Overall, BMI and treatment regimens received in 3L were associated with mTOT and mOS.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy of an anti-EGFR after ctDNA conversion from mutated RAS status of metastatic colorectal cancer: Results of a pilot study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4138;
Overall, BMI and treatment regimens received in 3L were associated with mTOT and mOS. The introduction of an anti-EGFR could provide an additional treatment option for patients with metastatic colorectal cancer with apparent conversion of initial RAS mutation, based on ctDNA assessment after prior failure on anti-EGFR-free chemotherapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Real-world time on treatment and overall survival in patients with metastatic colorectal cancer receiving cetuximab in second line after failing irinotecan or oxaliplatin-based regimens. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4133;
These patients were mostly male, < 65 years, and majority received FOLFOX regimens in 1L therapy . Key factors associated with TOT and OS were treatment regimens received in 1L and 2L .
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
[VIRTUAL] A retrospective study of local hepatic artery infusion chemotherapy combined with regorafenib in the treatment of advanced colorectal cancer with predominant liver metastases. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4128;
It also indicated a new promising treatment strategy for late stage CRC . Additional prospective and large-scale studies are required for further confirmation.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wi̇ld-type patients treated with biologics first- line metastatic colorectal cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4126;
This analysis of real-world data confirms the comparable efficacy of anti-EGFR agents in RAS-wild type mCRC . However, anti-EGFR treatment provides PFS and OS advantage when compared with anti-VEGF treatment in these patients.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] KRAS, NRAS and BRAF mutational status and first line treatment patterns in Slovenian population with metastatic colorectal carcinoma: Five year results. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4111;
Based on this, we conclude that the treatment decision in Slovenian population with metastatic colorectal carcinoma should be in the accordance with international treatment guidelines and on evidence based medicine . The molecular analysis performed at the Institute of Oncology Ljubljana was providing necessary biomarkers status report in an acceptable time that didn’t affect the treatment decision or delay the needed cancer treatment.
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4097;
This is the first finding for a potential biomarker in this subgroup using RNA-seq analysis tools . These findings will require additional validation.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4092;
We analyzed next-generation sequencing results in 520 cancer-associated genes for 22 patients who had BRAF V600E mutant mCRC in order to characterize genomic predictors of treatment outcome and track the acquired resistance (AR) mechanisms during the vemurafenib/dabrafenib/encorafenib treatment in combination with cetuximab +/- trametinib . Our study illustrated the landscape of genetic alterations in patients with BRAF V600E mutant mCRC upon BRAF inhibitor treatment, which could be critical to predict responses to BRAF inhibitors and guide personalized clinical decision-making after disease progression.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Global BRAF testing practices in metastatic colorectal cancer (mCRC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4088;
BRAF testing has global variability, impacting treatment decisions . Increased awareness and routine testing may lead to informed decisions regarding targeted therapies, such as encorafenib + cetuximab (where approved), in patients with BRAF V600E-mutant mCRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Successful salvage therapy with cetuximab-based modalities in the non-sensitive EGFR-mutant lung cancer patients with leptomeningeal metastasis who have heavily pretreated histories. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3873;
Their therapies were changed to cetuximab combined with TKI of afatinib or osimertinib, and local treatment including local radiation, intraventricular pemetrexed administration, or with intrathoracic drain . Cetuximab-based systemic therapy combined with local treatment demonstrated preliminary clinical activity in the rare EGFR-mutant lung cancer with LM who have already undergone heavily previous therapy, warranting further investigation.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Question : besides the negative cetuximab/chemotherapy trial In an unselected population, is there any appetite for a specific EGFR-amplified metastatic GEA study? (Twitter) - Apr 29, 2021
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
I second FOLFIRI + cetuximab (Twitter) - Apr 29, 2021
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: HER2-HER3 heterodimer quantification by FRET-FLIM and patient subclass analysis of the COIN colorectal trial. (Pubmed Central) - Apr 29, 2021
Our work suggests that the combined use of HER dimer imaging and conventional mutation analyses will be able to identify a small subclass of patients (>10%) who will have better prognosis following chemotherapy. A larger prospective cohort will be required to confirm its utility in predicting the outcome of anti-EGFR treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. (Pubmed Central) - Apr 29, 2021
Radiomics response signature can serve as an intermediate surrogate marker of overall survival. The signature outperformed known biomarkers in providing an early prediction of treatment-sensitivity and could be used to guide cetuximab treatment continuation decisions.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. (Pubmed Central) - Apr 29, 2021
In patients with wild-type KRAS, the four drugs exhibited significantly better OS and PFS than the placebo group, with the exception of OS with panitumumab treatment. Fruquintinib exhibited better PFS, good tolerability and reduced gastrointestinal adverse effects in wild-type KRAS subgroup, making it a promising agent to treat patients with wild-type KRAS mCRC beyond the second line.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy. (Pubmed Central) - Apr 29, 2021
Low SMM has no predictive value for cetuximab DLT in HNSCC patients. Low SMM is probably not a prognostic factor for overall survival in highly selected HNSCC patients treated with concomitant cetuximab and radiotherapy and unfit for platin-based chemotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Epidermal growth factor regulates the development of stem and progenitor Leydig cells in rats. (Pubmed Central) - Apr 29, 2021
It was found that EGF acted as a proliferative agent via increasing phosphorylation of AKT1. In conclusion, EGF stimulates the proliferation of rat stem and progenitor Leydig cells but blocks their differentiation.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. (Pubmed Central) - Apr 29, 2021
Finally, treatment with cetuximab reduced in vivo CASKI xenografted-tumor growth in nude mice, and decreased intratumoral uPA expression, while TM expression was unaltered. In conclusion, we showed that EGFR signaling regulated expression of the fibrinolytic system component uPA in both in vitro and in vivo settings, while uPA also participated in cell-morphology modifications and migration in a human cervical cancer model.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2541;
P2
As of February 12, 2021, 64 pts have been randomized . Planned safety data review for the first 10 pts treated with NIVOTAX regimen did not show any unexpected AE.
- Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2506;
P1
NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options . NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2497;
PCC is a relatively well-tolerated combination with a very good induction success rate . More research is needed around alternate options for frail and elderly patients with HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2493;
Pts with R/M HNSCC who progressed on ICI experience longer PFS with the addition of cetuximab to weekly chemotherapy . Further investigation in a larger cohort of pts is needed to fully assess the impact on survival for this treatment combination.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2488;
Most patients receiving neoadjuvant systemic therapy on window trials prior to surgery met all oncologic quality markers . Importantly, even with brief window trial therapy pathologic downstaging was achieved and associated with significantly better overall survival.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2470;
P1/2
The clinical trial met its primary endpoint of 1-year OS . Our data indicate the combination of CTX and NIVO is safe and effective in pts with previously untreated incurable R/M HNSCC.
- ficlatuzumab (AV-299) / AVEO, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2468;
P2
Our data indicate the combination of CTX and NIVO is safe and effective in pts with previously untreated incurable R/M HNSCC. The well-tolerated FC combination met the primary PFS endpoint in pan-refractory, advanced HNSCC with notable activity in HPV- HNSCC, warranting phase III investigation.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2465;
P3
For patients with low risk HPV associated oropharyngeal cancer, radiotherapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared to radiotherapy and weekly cisplatin . Radiotherapy and cisplatin remains the standard of care.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2443;
P3
Study tx and endpoints are shown in the table . Enrollment began on 6 January 2021.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tepmetko (tepotinib) / EMD Serono
[VIRTUAL] PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2441;
P1/2, P2
Retrospective assessment of best overall response, DoR and PFS by an independent review committee may be conducted . No formal statistical hypothesis will be tested in this exploratory study.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2435;
The higher severity in HFS with the addition of cetuximab appears to be related to higher grade but not chronic HFS . This method may be useful to describe different strategies, e.g .
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2416;
In contrast to TILs, adiponectin was not independently associated with patient outcome . Nearly one-half of stage III patients were vitamin D insufficient, although 25(OH)D was not prognostic.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy forBRAF V600E-mutant metastatic colorectal cancer (mCRC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2408;
P3
In the BEACON CRC study, pts treated with the doublet for BRAF V600E-mutant mCRC demonstrated similar OS regardless of prior therapies or duration of prior therapy use . This exploratory post-hoc analysis provides data that reflect the prior treatment landscape clinicians may face when deciding subsequent treatment regimens for pts with BRAF V600E-mutant mCRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2406;
Our study demonstrated for the first time that PPP2R4 polymorphisms could predict outcomes of bev-based treatment in mCRC patients; Meanwhile CIP2A polymorphism could predict outcomes of cet-based treatment in mCRC patients . These findings support a possible role of the PP2A variants in contributing to resistance to anti-VEGF/EGFR treatment.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2403;
P2
Cetuximab plus avelumab is effective and well tolerated as rechallenge treatment in mCRC . ST is a clinical biomarker for the identification of RAS/BRAF mCRC patients that could benefit from anti-EGFR rechallenge.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2402;
The clinical outcome resulted consistent with the literature data . In addition to the molecular selection through the analysis of ct-DNA for RAS, previous response to anti EGFR treatment is confirmed as a prospective selection criteria for this therapeutic option.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2363;
In addition to the molecular selection through the analysis of ct-DNA for RAS, previous response to anti EGFR treatment is confirmed as a prospective selection criteria for this therapeutic option. Our study demonstrates for the first time that STING and IFNB1 polymorphisms could predict outcomes of Cetuximab-based treatment in mCRC patients; These finding may provide insight for the combination of STING agonist and anti-EGFR treatment in mCRC patients.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2341;
In pts treated with Bev- and Cet-combination therapies that are standard of care, immune signatures affect response to therapy . These results, provide new markers for treatment selection and for the development of novel active combinations including immune checkpoint inhibitors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2340;
While selective pressure appears to increase the frequency of acquired MTs in the 3L setting, preexisting subclonal MTs do not appear to be the dominant source of acquired MTs at progression, implying that there may also be a transient mutational process driving resistance rather than expansion of preexisting clones . These findings have significant implications for ongoing and planned EGFRi rechallenge studies.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2339;
P3
Molecular characteristics and biological properties observed in BRAF V600E-mutant mCRC suggest that a subset of pts with specific molecular features may derive greater clinical benefit from triplet than doublet therapy . Additionally, these findings support the utility of gaining further understanding of the biological landscape in BRAF-mutant mCRC to enable potential hypotheses for pt selection to improve clinical outcome in future studies.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2320;
P2
FIRE-4.5 is the first prospective and randomized study investigating efficacy of FOLFOXIRI combined with targeted therapy in the first-line treatment of BRAF V600E-mutant mCRC . FOLFOXIRI plus either bevacizumab or cetuximab have comparable efficacy with differential effects according to primary tumor sidedness supporting the heterogeneity of BRAF V600E-mutant subpopulation of mCRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2319;
This trial was a randomized phase II trial to evaluate modified (m)-FOLFOXIRI (irinotecan 150mg/m2, oxaliplatin 85mg/m2, 5-FU 2400mg/m2) plus cet vs... The mFOLFOXIRI plus cet has been shown to be significantly superior to the mFOLFOXIRI plus bev in terms of DpR as the primary endpoint in first-line treatment for RAS wild-type mCRC.
- Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2318;
P3
As 1L therapy for pts with MSI-H/dMMR mCRC, pembro vs chemo provides statistically superior PFS with fewer TRAEs, and is associated with a trend toward reduced mortality that did not meet statistical significance likely due to the high crossover rate from chemo to anti-PD1/PD-L1 therapies . Together these data confirm pembro as a new standard-of-care in the 1L for pts with MSI-H/dMMR mCRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy of cetuximab after immunotherapy (IO) in advanced cutaneous squamous cell carcinoma (CSCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1867;
If validated in a larger dataset, this should be the preferred therapy for second-line treatment in advanced CSCC . Further exploration into the mechanism of this high efficacy of anti-EGFR therapy post aPD1 therapy is warranted.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1286;
In a low risk population CIS/RT achieves excellent outcomes in both high and low ITIC CD103 groups . The high ITIC CD103 population is a rational target for future de-intensification trials.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1147;
Molecular profiling would probably be of high interest in this setting . This series may serve as a benchmark for future clinical trials in chordoma.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
[VIRTUAL] Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1086;
P2
Supportive medication consisted of minocycline, loperamide and skin creams . Combination treatment with afatinib and cetuximab demonstrated antitumor activity with a DCR of 59% at 18 weeks and a 47% RR, with manageable toxicity.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_962;
P1/2
NT219 provides a first-in-class treatment for patients with resistant neoplastic disease . The current trial will provide important data in patients with recurrent/metastatic cancers, particularly, HNSCC on the effects of the inhibition of STAT3 and IRS1/2 pathways as a novel therapeutic approach.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Not sure it is 1 to 1 ... but if someone has meat allergy ( mammalian meat only) , then avoid cetuximab ... (Twitter) - Apr 28, 2021